Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation

Tracy T. Batchelor, Elizabeth R. Gerstner, Kyrre E. Emblem, Dan G. Duda, Jayashree Kalpathy-Cramer, Matija Snuderl, Marek Ancukiewicz, Pavlina Polaskova, Marco C. Pinho, Dominique Jennings, Scott R. Plotkin, Andrew S. Chi, April F. Eichler, Jorg Dietrich, Fred H. Hochberg, Christine Lu-Emerson, A. John Iafrate, S. Percy Ivy, Bruce R. Rosen, Jay S. LoefflerPatrick Y. Wen, A. Greg Sorensen, Rakesh K. Jain

Research output: Contribution to journalArticlepeer-review

277 Scopus citations


Antiangiogenic therapy has shown clear activity and improved survival benefit for certain tumor types. However, an incomplete understanding of the mechanisms of action of antiangiogenic agents has hindered optimization and broader application of this new therapeutic modality. In particular, the impact of antiangiogenic therapy on tumor blood flow and oxygenation status (i.e., the role of vessel pruning versus normalization) remains controversial. This controversy has become critical as multiple phase III trials of anti- VEGF agents combined with cytotoxics failed to show overall survival benefit in newly diagnosed glioblastoma (nGBM) patients and several other cancers. Here, we shed light on mechanisms of nGBM response to cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, using MRI techniques and blood biomarkers in prospective phase II clinical trials of cediranib with chemoradiation vs. chemoradiation alone in nGBM patients. We demonstrate that improved perfusion occurs only in a subset of patients in cediranib-containing regimens, and is associated with improved overall survival in these nGBM patients. Moreover, an increase in perfusion is associated with improved tumor oxygenation status as well as with pharmacodynamic biomarkers, such as changes in plasma placenta growth factor and sVEGFR2. Finally, treatment resistance was associated with elevated plasma IL-8 and sVEGFR1 posttherapy. In conclusion, tumor perfusion changes after antiangiogenic therapy may distinguish responders vs. nonresponders early in the course of this expensive and potentially toxic formof therapy, and these results may provide newinsight into the selection of glioblastoma patients most likely to benefit from anti-VEGF treatments.

Original languageEnglish (US)
Pages (from-to)19059-19064
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number47
StatePublished - Nov 19 2013
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation'. Together they form a unique fingerprint.

Cite this